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Orally administered nitrite exerts antihypertensive effects associated with increased gastric nitric oxide
(NO) formation. While reducing agents facilitate NO formation from nitrite, no previous study has
examined whether antioxidants with reducing properties improve the antihypertensive responses to
orally administered nitrite. We hypothesized that TEMPOL (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-
oxyl) could enhance the hypotensive effects of nitrite in hypertensive rats by exerting antioxidant effects
(and enhancing NO bioavailability) and by promoting gastric nitrite-derived NO generation. The
hypotensive effects of intravenous and oral sodium nitrite were assessed in unanesthetized freely
moving rats with L-NAME (Nω-nitro-L-arginine methyl ester; 100 mg/kg; po)-induced hypertension
treated with TEMPOL (18 mg/kg; po) or vehicle. While TEMPOL exerted antioxidant effects in
hypertensive rats, as revealed by lower plasma 8-isoprostane and vascular reactive oxygen species
levels, this antioxidant did not affect the hypotensive responses to intravenous nitrite. Conversely,
TEMPOL enhanced the dose-dependent hypotensive responses to orally administered nitrite, and this
effect was associated with higher increases in plasma nitrite and lower increases in plasma nitrate
concentrations. In vitro experiments using electrochemical and chemiluminescence NO detection under
variable pH conditions showed that TEMPOL enhanced nitrite-derived NO formation, especially at low
pH (2.0 to 4.0). TEMPOL signal evaluated by electron paramagnetic resonance decreased when nitrite was
reduced to NO under acidic conditions. Consistent with these ﬁndings, increasing gastric pH with
omeprazole (30 mg/kg; po) attenuated the hypotensive responses to nitrite and blunted the enhance-
ment in plasma nitrite concentrations and hypotensive effects induced by TEMPOL. Nitrite-derived NO
formation in vivo was conﬁrmed by using the NO scavenger 2-(4-carboxyphenyl)-4,4,5,5-tetramethyli-
midazoline-1-oxyl-3-oxide (C-PTIO), which blunted the responses to oral nitrite. Our results showed that
TEMPOL promotes nitrite reduction to NO in the stomach and enhanced plasma nitrite concentrations
and the hypotensive effects of oral sodium nitrite through mechanisms critically dependent on gastric
pH. Interestingly, the effects of TEMPOL on nitrite-mediated hypotension cannot be explained by
increased NO formation in the stomach alone, but rather appear more directly related to increased
plasma nitrite levels and reduced nitrate levels during TEMPOL treatment. This may relate to enhanced
nitrite uptake or reduced nitrate formation from NO or nitrite.
& 2013 Elsevier Inc. All rights reserved.Introduction
Nitric oxide (NO) is oxidized to form the anions nitrite (NO2)
and nitrate (NO3) [1]. While those anions were considered asll rights reserved.
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@yahoo.comrelatively inactive oxidation products of NO in the past, it is now
widely acknowledged that they can recycle back to NO, and that a
nitrate-nitrite-NO pathway plays a major role in physiological and
pathological NO formation independent of NO synthases [2–4].
These ﬁndings have now brought increased attention to the
relevance of dietary nitrite or nitrate, which directly, or after
reduction of nitrate to nitrite by oral bacteria, promote NO
formation under the acidic conditions of the stomach [5,6].
In a seminal study showing that ingestion of lettuce increased
intragastric nonenzymatic NO production, Lundberg et al. clearly
veriﬁed the major importance of low gastric pH for NO formation
[7]. While the hypotensive effects of nitrite likely involve bioacti-
vation of plasma nitrite, the mechanisms explaining how orally
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entirely known and may depend, at least in part, on gastric NO
formation [8]. Indeed, we have recently shown that treatment
with omeprazole (a gastric proton pump inhibitor) increased
gastric pH and attenuated the hypotensive effects of oral nitrite
administration [9], thus aligning with those initial fundamental
ﬁndings [7] and showing that the acidic conditions of the stomach
are very important for the hypotensive effects of oral nitrite. In this
respect, factors other than the gastric pH may affect NO formation
from nitrite [10,11]. Indeed, reducing agents may facilitate NO
formation from nitrite [12], and it is possible that antioxidant
drugs with reducing properties may improve the responses to
orally administered nitrite. However, few studies have examined
the cardiovascular implications of interactions between antioxi-
dant drugs with reducing properties and nitrite, particularly under
the acidic conditions of the stomach [13,14]. Here, we hypothe-
sized that TEMPOL, a water-soluble, paramagnetic nitroxyl radical
with superoxide dismutase (SOD) mimetic activity [15], could
enhance nitrite-derived NO generation under acidic conditions of
the stomach and therefore enhance the hypotensive effects of
orally administered sodium nitrite. This hypothesis is supported by
a recent study showing that dietary polyphenols may favor NO
formation from nitrite under low pH conditions [14]. In addition,
we also hypothesized that the antioxidant effects of TEMPOL could
increase NO bioavailability and enhance the responses to intrave-
nous nitrite.
To test these hypotheses, we examined the hypotensive effects
of sodium nitrite (both intravenously and orally) in unanesthetized
freely moving rats with L-NAME (Nω -nitro-L-arginine methyl
ester)-induced hypertension that were treated with TEMPOL or
vehicle. While this antioxidant did not enhance the effects of
intravenous nitrite, TEMPOL enhanced orally administered nitrite-
induced hypotension and increases in plasma nitrite concentra-
tions. These effects were critically dependent on gastric acidic
conditions. In vitro experiments conﬁrmed in vivo ﬁndings, and
TEMPOL enhanced nitrite-derived NO only under acidic
conditions.Materials and methods
Animals and treatments
This study was approved by the Institutional Animal Care and
Use Committee of the Faculty of Medicine of Ribeirao Preto,
University of Sao Paulo, and the animals were handled according
to the guiding principles published by the National Institutes of
Health. Male Wistar rats (200–250 g) obtained from the colony at
University of São Paulo (Ribeirao Preto Campus, Brazil) were
maintained on a 12-h light/dark cycle at a room temperature
(22–25 1C) with free access to standard rat chow and water.
Assessment of mean arterial pressure (MAP) in unanesthetized freely
moving rats
One day before the experiments, the animals were anesthe-
tized with tribromoethanol (250 mg/kg, ip) and the femoral artery
was cannulated (3 cm segment of a PE-10 tube connected to 14 cm
of a PE-50 tubing; Clay Adams, Parsippany, NJ, USA). The catheter
was then tunneled subcutaneously and exteriorized through the
back of the neck. In some experiments, the femoral vein also was
cannulated following the same procedures for drug infusions.
After surgery, the nonsteroidal anti-inﬂammatory ﬂunixine
meglumine (2.5 mg/kg, sc, Banamine, Schering Plough, Brazil)
was administered for postoperation analgesia. Following 12 h of
fasting, the arterial cannula was connected to a pressuretransducer and the MAP in freely moving rats was recorded using
a data acquisition system (MP150CE; Biopac Systems Inc., CA, USA)
connected to a computer (Acknowledge 3.2, for Windows). Before
collecting data, we allowed at least 15 min of stabilization before
or after each oral gavage.
Effects of TEMPOL on the hypotensive responses to intravenously
administered sodium nitrite
Because TEMPOL (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-
oxyl) exerts antioxidant effects, we examined whether TEMPOL
enhances the hypotensive effects of intravenously administered
sodium nitrite in rats with L-NAME (Nω -nitro-L-arginine methyl
ester hydrochloride)-induced hypertension. Therefore, the rats
received a single gavage of L-NAME (100 mg/kg) to increase the
MAP. This dose of L-NAME was chosen based on pilot studies
showing that it increases MAP by approximately 40 mm Hg. Thirty
minutes after L-NAME treatment, the rats received vehicle or
TEMPOL (18 mg/kg) by gavage, and 15 min later the rats received
vehicle or cumulative doses of sodium nitrite (0, 0.16, 0.5, 1.6, 5,
and 15 mg/kg) [9] intravenously. Each dose was injected every
15 min and the maximum changes in MAP were analyzed.
Measurment of 8-isoprostane levels in plasma and vascular reactive
oxygen species (ROS) production to assess antioxidant effects
of TEMPOL
To examine antioxidant effects exerted by TEMPOL, plasma
samples from rats were used to measure 8-isoprostanes (8-
isoPGF2α) concentrations. The measurements were carried out as
previously described [16], with commercially available enzyme-
linked immunosorbent assay kits (Cayman Chemical Co., Ann
Arbor, MI, USA).
To assess vascular oxidative stress, ROS production in the aorta
from animals was measured by dihydroethidium (DHE), a ROS-
sensitive ﬂuorescent dye, as previously described [17]. Aortic
cryosections (5 μm thick) were incubated at room temperature
with DHE (10 μmol/L) for 30 min. Sections were examined by
ﬂuorescence microscopy (Leica Imaging Systems Ltd., Cambridge,
UK) and the image was captured at 400. Red ﬂuorescence from
20 ﬁelds around the vessels was evaluated using ImageJ software
(http://rsbweb.nih.gov/ij/).
Effects of TEMPOL on orally administered sodium nitrite-induced
hypotension
Because TEMPOL did not enhance the hypotensive effects of
intravenously administered sodium nitrite, we examined whether
pretreatment with TEMPOL enhances the hypotensive effects of
orally administered sodium nitrite in rats with L-NAME-induced
hypertension. Therefore, the rats received the same oral dose of
L-NAME and TEMPOL described above, and 15 min later the rats
received vehicle or sodium nitrite (0, 1.6, 5, or 15 mg/kg, by
gavage) [9], and the changes in MAP were evaluated for 10 min.
Then the animals were sacriﬁced to collect their aorta and blood
samples.
At the end of experiments, arterial blood samples were col-
lected into tubes containing heparin and immediately centrifuged
at 1000 g for 3 min. The plasma samples were stored at 70 1C
until used to measure plasma nitrite and nitrate concentrations as
described below.
Measurement of plasma nitrite and plasma nitrate concentrations
Plasma aliquots were analyzed in duplicate for their nitrite
content using an ozone-based reductive chemiluminescence assay
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tions in plasma, 50 ml of plasma samples was injected into a
solution of acidiﬁed tri-iodide, purging with nitrogen in-line with
a gas-phase chemiluminescence NO analyzer (Sievers Model 280
NO analyzer, Boulder, CO, USA). Approximately 8 ml of tri-iodide
solution (2 g potassium iodide and 1.3 g iodine dissolved in 40 ml
water with 140 ml acetic acid) was placed in the purge vessel into
which plasma samples were injected. The data were analyzed
using the software Origin Lab 6.1.
We measured plasma nitrite + nitrate concentrations in dupli-
cate by using the Griess reaction as described previously [19].
Brieﬂy, 40 μl of plasma was incubated with the same volume of
nitrate reductase buffer (0.1 M potassium phosphate, pH 7.5,
containing 1 mM beta nicotinamide adenine dinucleotide phos-
phate, and 2 units of nitrate reductase/ml) in individual wells of a
96-well plate. Samples were allowed to incubate overnight at
37 1C in the dark. Eighty microliters of freshly prepared Griess
reagent (1% sulfanilamide, 0.1% naphthylethylenediamine dihy-
drochloride in 5% phosphoric acid) was added to each well and the
plate was incubated for an additional 15 min at room temperature.
A standard nitrate curve was obtained by incubating sodium
nitrate (0.2–200 mM) with the same reductase buffer. To calculated
plasma nitrite concentrations, we subtracted plasma nitrite
concentrations measured by chemiluminescence plasma nitrite
+ nitrate concentrations measured by Griess reaction.
Assessment of in vitro effects of TEMPOL on nitric oxide formation
from sodium nitrite in a simulated gastric juice solution
(electrochemical and chemiluminescence NO detection)
To examine whether TEMPOL affects nitric oxide formation
from sodium nitrite in vitro, we used a Clark-type electrochemical
NO sensor amiNO-700 (inNO-T Analyzer, Innovative Instruments
Inc., Tampa, FL, USA), which was inserted into a simulated gastric
juice (SGJ) solution, as previously described [14]. The SGJ solution
contained HCl 7 mM and NaCl 50 mM in distilled water, and the
pH was adjusted to 2.0 by adding HCl [14]. NO formation was
detected by using 2 ml of SGJ solution containing NaNO2 (20 mM)
in the absence or presence of TEMPOL (0, 2, 20, and 200 mM)
actively mixed with a magnetic stirrer.
To further conﬁrm the ﬁndings obtained with the Clark-type
electrochemical NO sensor, we carried out experiments with NO
detection by chemiluminescence using the Sievers NO analyzer.
Brieﬂy, we examined whether TEMPOL increases NO formation
from sodium nitrite. Therefore, we prepared the same SGJ
described above and sodium nitrite (0, 1, and 10 mM) was added
to the SGJ solution containing TEMPOL 20 mM. The maximum
chemiluminescence signal (mV) was measured after each sodium
nitrite injection.
Effects of sodium nitrite concentrations on TEMPOL signal detected
by electron paramagnetic resonance (EPR)
TEMPOL may be converted into other compounds and therefore
EPR spectroscopy was carried out to assess TEMPOL concentra-
tions in solutions containing sodium nitrite. EPR measurements
were performed in a JEOL FA-200 spectrometer equipped with a
rectangular cavity. Data acquisition parameters included ﬁeld
modulation amplitude, 0.6 G; time constant, 0.03 s; sweep time,
60 s; sweep width, 75 G; and microwave power 10 mW. These
parameters were set to maximize signal-to-noise ratio and to
avoid distortion and/or saturation of EPR signal [20]. EPR spectra
were measured at room temperature.
An aliquot of 50 ml of an aqueous solution (water or SGJ, as
described above) containing TEMPOL (100 mM) and sodium nitrite
(0, 3, 10, 30, 100, or 300 mM) was transferred to a glass capillaryand taken into an EPR cylindrical quartz tube. EPR signal intensity
was measured in triplicate as the peak-to-peak height of the
central-ﬁeld EPR lines, using the software provided with the JEOL
spectrometer.Effects of TEMPOL on pH-dependent nitric oxide formation from
sodium nitrite in a simulated gastric juice solution
To examine how pH modiﬁes the effects of TEMPOL on sodium
nitrite-derived NO formation, we measured NO formation using
the Clark-type electrochemical NO sensor as described above. SGJ
solutions with pH varying from 2.0 to 7.0 were prepared as
described above. Vehicle or TEMPOL 20 mM was added to the SGJ
solutions, and NO formation was measured after sodium nitrite
20 mM was added to the solutions.Effects of increased gastric pH on the changes in the hypotensive
effects of sodium nitrite induced by TEMPOL
To examine how gastric pH affects the TEMPOL-induced
changes in the hypotensive effects of nitrite, we examined
whether pretreatment with omeprazole (a proton pump inhibitor)
modiﬁes the effects of TEMPOL on sodium nitrite (15 mg/kg)-
induced hypotension found with protocol 1. Therefore, rats
received a single gavage of omeprazole (30 mg/kg) or vehicle
(1 ml/kg of 2% Tween 80), and the procedures described in ﬁrst
protocol were repeated 1 h after the administration of vehicle or
omeprazole. The dose of omeprazole was chosen based on
previous ﬁndings showing that this dose attenuated the effects
of nitrite [9]. To assess the effects of omeprazole on gastric pH, we
measured gastric washing pH as previously detailed [9].
In addition, to examine how gastric pH affects the increases in
plasma nitrite and nitrate concentrations in rats treated with
TEMPOL and nitrite, we measured the concentrations of both
products of NO oxidation as described above.Effects of NO scavenger C-PTIO on the hypotensive effects of sodium
nitrite with or without TEMPOL
To examine whether the hypotensive effects of sodium nitrite
in the presence or absence of TEMPOL are mediated by NO
formation from nitrite, we repeated the experiments described
in ﬁrst protocol in rats infused with the NO scavenger 2-(4-
carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide
(0.2 mg/kg/min) or saline (50 ml/min). In addition, as a positive
control, we examined the effects of the same infusion of C-PTIO in
hypertensive rats treated with DETANONOate (17 mg/kg).Drugs and solutions
All drugs and reagents were purchased from Sigma Chemical
Co. (St Louis, MO, USA) and all solutions were prepared immedi-
ately before use.Statistical analysis
The results are expressed as means 7 SEM. The comparisons
between groups were assessed by two-way analysis of variance
using Bonferroni correction or one-way analysis of variance
followed by Dunnett's multiple comparison tests. A probability
value o0.05 was considered signiﬁcant. Statistical analyses were
carried out using the GraphPad PRISM software (GraphPad Prism,
Software Inc., San Diego, CA, USA).
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Antioxidant effects of TEMPOL are not associated with increased
hypotensive effects to intravenously administered sodium nitrite
in hypertensive animals
To test the possibility that the antioxidant TEMPOL enhances
the responses to intravenously administered sodium nitrite, weFig. 1. Changes in mean arterial pressure (MAP) measured in unanesthetized free-
moving hypertensive rats in response to increasing doses of intravenously admi-
nistered NaNO2. The rats received L-NAME (100 mg/kg, by gavage) to increase MAP
by approximately 40 mm Hg, followed 30 min later by saline or TEMPOL (18 mg/kg;
by gavage). The maximum changes in MAP in response to cumulative doses of
NaNO2 (0.16, 0.5, 1.6, 5, and 15 mg/kg; injected intravenously every 15 min) were
not modiﬁed by pretreatment with TEMPOL. The upper panel shows the MAP
results and the lower panel shows the changes in MAP after each dose of NaNO2.
Data are shown as mean 7 SEM (n¼5 per group). nPo0.05 for TEMPOL versus
Vehicle.
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Control + Vehicle. # Po0.05 versus L-NAME + Vehicle.examined the responses to increasing doses of sodium nitrite in
rats with L-NAME-induced hypertension that were pretreated
with TEMPOL (or vehicle). While sodium nitrite induced dose-
dependent hypotensive responses (Po0.05; Fig. 1), pretreatment
with TEMPOL did not enhance the responses to any dose of
intravenous nitrite (P40.05; Fig. 1).
While TEMPOL had no effects on the responses to intravenous
nitrite, this antioxidant clearly decreased markers of oxidative
stress. Whereas L-NAME hypertensive animals showed higher 8-
isoprostane levels in plasma and increased aortic ROS levels than
normotensive controls (both Po0.05; Fig. 2A–C), treatment with
TEMPOL reduced 8-isoprostane levels and blunted the increases in
aortic ROS levels associated with hypertension (both Po0.05;
Fig. 2A–C).TEMPOL enhances the acute hypotensive effects of oral sodium nitrite
and the increases in circulating nitrite concentrations
We examined the possibility that TEMPOL could enhance the
hypotensive effects of oral sodium nitrite in hypertensive animals.
Whereas no signiﬁcant changes in MAP were seen in the groups
treated with vehicle or TEMPOL only (data not shown), treatment
of L-NAME hypertensive rats with sodium nitrite induced dose-
dependent decreases in MAP (Fig. 3). Treatment with TEMPOL
signiﬁcantly increased the hypotensive effects of sodium nitrite at
1.6, 5, and 15 mg/kg (all Po0.05; Fig. 3).
The effects of TEMPOL on the circulating levels of nitrite or
nitrate were examined in hypertensive animals treated with oral
sodium nitrite. While treatment with sodium nitrite increased
plasma nitrite and nitrate concentrations in a dose-dependent
manner, pretreatment with TEMPOL was associated with higher
increases in plasma nitrite concentrations and with lower
increases in plasma nitrate concentrations in animals treated
sodium nitrite at 5 or 15 mg/kg (all Po0.05; Fig. 4A and B).TEMPOL facilitates nitrite-derived NO formation in vitro in a
simulated gastric juice solution and its EPR signal decreases
with increasing nitrite concentrations
To examine whether TEMPOL enhances sodium nitrite-induced
hypotension in vivo through mechanisms facilitating nitrite-
derived NO, we used two independent methods to study the
in vitro effects of TEMPOL on NO formation from sodium nitriteControl Control + 
Tempol 
ME L-NAME
L-NAME L-NAME+
Tempol
cle
+
Tempol
ssessed by dihydroethidium (DHE) ﬂuorescence. Panel A shows 8-isoprostanes
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ium by O2 . Data are shown as mean 7 SEM (n¼5 per group). nPo0.05 versus
Fig. 3. Changes in mean arterial pressure (MAP) measured in unanesthetized free-
moving hypertensive rats in response to variable doses of NaNO2. The rats received
L-NAME (100 mg/kg, by gavage) to increase MAP by approximately 40 mm Hg,
followed 30 min later by saline or TEMPOL (18 mg/kg; by gavage). Ten minutes
later, the changes in MAP in response to NaNO2 (1.6, 5, or 15 mg/kg, by gavage)
were recorded. The upper panel shows the baseline and MAP after each dose of
NaNO2, whereas the lower panel shows the changes in MAP after each dose of
NaNO2. Data are shown as mean 7 SEM (n¼4–6 per group). nPo0.05 for TEMPOL
versus Vehicle.
Fig. 4. Plasma nitrite concentrations (mmol/l; upper panel) and plasma nitrate
concentrations (mmol/L; lower panel) in rats that received vehicle (saline) or
TEMPOL (18 mg/kg) followed 10 min later by NaNO2 (0, 1.6, 5, and 15 mg/kg, by
gavage). Blood samples were collected 20 after nitrite gavage. Data are shown as
mean 7 SEM (n¼4–6 per group). nPo0.05 for TEMPOL versus Vehicle.
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obtained with a Clark-type electrochemical NO sensor show that
TEMPOL facilitates NO formation from sodium nitrite in a
concentration-dependent manner (Fig. 5; Po0.05). In line with
these ﬁndings, the chemiluminescence results conﬁrmed that
TEMPOL increases sodium nitrite-derived NO at different concen-
trations (Po0.05; Fig. 6A–C).
Because TEMPOL may be converted into other compounds, we
used EPR to assess TEMPOL concentrations in solutions (water or
SGJ) containing sodium nitrite. We found no signiﬁcant differences
in the EPR signal when TEMPOL was incubated at pH 7.2 (SGJ) or
2.0 (3053077089 versus 2735076213 arbitrary units, respec-
tively; P40.05). While the EPR signal was not modiﬁed when
TEMPOL was incubated with sodium nitrite (0–300 mM) in water
(P40.05; Fig. 6D), TEMPOL EPR signal decreased in a
concentration-dependent manner when TEMPOL was incubated
with the same concentrations of sodium nitrite in pH 2.0 SGJ
solutions (Po0.05; Fig. 6D and E).TEMPOL enhances nitrite-derived in vitro NO formation
in a pH-dependent manner
We determined whether pH modiﬁes the effects of TEMPOL on
sodium nitrite-derived NO formation using a Clark-type electro-
chemical NO sensor. As expected, the amounts of nitrite-derived
NO were inversely associated with the pH of SGJ solutions, andTEMPOL signiﬁcantly enhanced NO formation at pH 2.0 to 4.0
(Po0.05; Fig. 7), but not at higher pH values.
Pretreatment with omeprazole attenuates the hypotension induced
by sodium nitrite and blunts the effects of TEMPOL
Because TEMPOL enhanced nitrite-derived NO formation only
under acidic conditions, we examined the effects of pretreatment
with omeprazole on TEMPOL-induced changes in the hypotensive
effects of nitrite in hypertensive rats. While TEMPOL enhanced the
hypotensive effect of sodium nitrite, pretreatment with omepra-
zole attenuated such effects (Fig. 8A; Po0.05). Importantly, pre-
treatment with omeprazole completely prevented TEMPOL from
enhancing the hypotensive effect of sodium nitrite (Fig. 8A).
To verify the effects of omeprazole on gastric pH, we measured
gastric washing pH, and we found that omeprazole increased the
gastric washing pH (Fig. 8B; Po0.05), and this effect was not
modiﬁed by TEMPOL or nitrite.
Because TEMPOL increased nitrite-induced hypotension, and
pretreatment with omeprazole blunted this effect, we examined
whether both drugs affect plasma nitrite and nitrate concentrations.
While the increases in plasma nitrite concentrations more than
doubled after nitrite administration in the presence of TEMPOL
(Fig. 8C; Po0.05), omeprazole had no effects on the increases in
nitrite concentrations (Fig. 8C; P40.05). Interestingly, omeprazole
completely blunted the enhancement in plasma nitrite concentra-
tions associated with TEMPOL (Fig. 8C; P40.05).
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found when nitrite was administered to animals pretreated
with TEMPOL (Fig. 8D; Po0.05), omeprazol alone had no effects
(Fig. 8D; P40.05) and it blunted the effects of TEMPOL (Fig. 8D;
Po0.05).NO scavenger C-PTIO almost completely blunted the hypotensive effects
of sodium nitrite and its enhanced effects in the presence of TEMPOL
The hypotensive effects of oral sodium nitrite were previously
blunted by C-PTIO, thus indicating NO formation [9], which could
J.H. Amaral et al. / Free Radical Biology and Medicine 65 (2013) 446–455452be increased by TEMPOL treatment. Fig. 9 shows hypotensive
effects of oral sodium nitrite (15 mg/kg), very similar to those
observed with DETANONOate (7.5 mg/kg; a positive control).
Pretreatment with TEMPOL (18 mg/kg) increased the effects of3300 Vehicle + NaNO2
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Fig. 7. Effect of simulated gastric juice (SGJ) solution pH on sodium nitrite-derived
NO production in the absence (open bars) or presence (closed bars) of TEMPOL. The
bars show NO production (as detected electrochemically by a Clark-type electrode)
from sodium nitrite (20 mM) and TEMPOL (20 mM) added to SGJ solutions with pH
varying from 2.0 to 7.0. Reduced NO if formed as pH increases from 2.0 to 7.0.
TEMPOL signiﬁcantly increased NO formation at pH 2.0, 3.0, and 4.0. Data are
shown as mean 7 SEM (n¼4–5 per group). nPo0.05 for TEMPOL + NaNO2 versus
Vehicle + NaNO2.
Fig. 8. Effects of omeprazole (30 mg/kg) and/or TEMPOL (18 mg/kg) on sodium nitrite (
washing pH (panel B), and on plasma nitrite (panel C) and nitrate (pane D) concentratio
and nitrate concentrations. After the same oral dose of nitrite, TEMPOL enhanced the hyp
it attenuated the increases in plasma nitrate concentrations. Treatment with omeprazol a
both nitrite-induced hypotensive effects and the increases in plasma nitrite concentrati
# Po0.05 versus TEMPOL + NaNO2.sodium nitrite (Po0.05; Fig. 9). However, C-PTIO attenuated the
hypotensive effects of sodium nitrite and DETANONOate, and
completely blunted the TEMPOL-enhanced hypotension (all
Po0.05; Fig. 9).Discussion
The main novelty reported here is that the antioxidant TEMPOL
promotes nitrite reduction to NO in the stomach, and enhances
plasma nitrite concentrations and its hypotensive effects after oral
nitrite administration, but not after intravenous administra-
tion. We show that this mechanism is critically dependent on
gastric pH.
Antihypertensive effects of oral nitrite were demonstrated in
spontaneously hypertensive rats (SHR) more than two decades ago
[21]. More recently, we and others showed consistent antihyper-
tensive effects of nitrite in different animal models, including L-
NAME-induced [22] and two-kidney, one-clip hypertension [23].
While vasodilatory effects of nitrite occur in various different
vascular beds, probably explaining its effects on blood pressure
[2,24,25], little is known about mechanisms converting nitrite into
NO in hypertension. In this respect, increased erythrocytic xantine
oxidoreductase activity leading to increased NO formation from
nitrite was shown in SHR [26]. Moreover, we showed that nitrite
downregulates vascular NADPH oxidase activity [23], and thus
may exert antioxidant effects. While the precise mechanisms
explaining vasodilatory and antihypertensive effects of nitrite in15 mg/kg)-induced decreases in mean arterial pressure (MAP; panel A), on gastric
ns. Vehicle (saline), TEMPOL, or omeprazole alone had no effects on MAP or nitrite
otensive effect of nitrite, and the increases in plasma nitrite concentrations, whereas
ttenuated the hypotensive effects of nitrite, and prevented TEMPOL from enhancing
ons. Data are shown as mean 7 SEM (n¼7–8 per group). nPo0.05 versus NaNO2.
J.H. Amaral et al. / Free Radical Biology and Medicine 65 (2013) 446–455 453hypertension are not entirely clear, upregulation of enzymatic and
nonenzymatic nitrite conversion into NO in the vascular wall
[27,28] may play a role, and possibly explain consistent dose-
dependent antihypertensive effects that we found in the
present study.
TEMPOL is a water-soluble, paramagnetic nitroxyl radical with
superoxide dismutase mimetic activity [15]. This drug is widely
used to study the role of oxidative stress in cardiovascular diseases
including hypertension [29,30], and its antihypertensive effects
have been attributed, at least in part, to its antioxidant properties,
which may improve NO bioavailability [30]. While our 8-isoprostanes
and aortic ROS results clearly show antioxidant effects of TEMPOL,
we found no hypotensive effects with the dose of TEMPOL used in
the present study. Indeed, antihypertensive effects of TEMPOL
are dose-dependent, and the dose we used is not expected to exert
antihypertensive effects [29,30]. In fact, we aimed at examining
whether TEMPOL enhances the hypotensive effects of sodium
nitrite, and therefore we decided to use a dose of TEMPOL without
signiﬁcant antihypertensive effects. In contrast to enhanced
responses to orally administered nitrite after pretreatment with
TEMPOL, this antioxidant did not enhance the effects of intravenous
nitrite, thus suggesting that systemic or vascular antioxidant
mechanisms are probably not involved in the enhanced responses
to orally administered nitrite in rats pretreated with TEMPOL.0
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Fig. 9. Infusion of NO scavenger carboxy-PTIO (C-PTIO) blunts the changes in mean
arterial pressure (MAP) induced by sodium nitrite. The ﬁgure shows the changes in
MAP induced by vehicle, TEMPOL (18 mg/kg), DETANONOate (7.5 mg/kg), sodium
nitrite (15mg/kg), or TEMPOL + sodium nitrite administered during saline or
C-PTIO infusion (0.2 mg/kg/min). Data are shown as mean 7 SEM (n¼5–7 per
group). #Po0.05 versus NaNO2. nPo0.05 for C-PTIO infusion group versus
respective saline infusion group.
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Fig. 10. Mechanisms possibly explaining how TEMPOL facilitates nitrite-derived gasTo study how TEMPOL affects nitrite-derived NO formation, we
carried out in vitro experiments at variable pH. We used two
different methods (electrochemical and chemiluminescence NO
detection) to clearly show that TEMPOL facilitates NO formation
from nitrite in a concentration-dependent manner, and this effect
increased with pH lowering. These results show that TEMPOL
facilitates nitrite reduction to NO, especially at low pH. While
nitrite disproportionation into NO has been known for a long time
[12], no previous study has examined whether TEMPOL affects this
reaction. Interestingly, we found that the EPR signal of TEMPOL
decreased in a nitrite concentration-dependent manner only at
low pH.
The in vitro effects of TEMPOL may explain how TEMPOL
facilitates the antihypertensive effects of oral nitrite. Interestingly,
we found that TEMPOL enhanced the increases in plasma nitrite
concentrations after all doses of oral sodium nitrite. Because nitrite
reduces blood pressure in a dose-dependent manner, it is reason-
able to believe that TEMPOL enhances the hypotensive effects of
oral nitrite simply by promoting conditions leading to higher
plasma nitrite concentrations (Fig. 10). This is valid for each and
every dose of oral sodium nitrite tested here. Although simplistic,
our in vitro experiments are consistent with the idea that TEMPOL
allows a more reducing environment in the stomach and enhances
gastric nitrite-derived NO formation in vivo. This effect results in
higher plasma nitrite levels and in more hypotension in the
presence of TEMPOL, possibly because nitrite is entering blood
circulation as nitrite or as another nitrite-derived species more
diffusible than nitrite, which may be oxidized back to nitrite in the
circulation. This effect may be strikingly potentiated by TEMPOL,
as our in vitro data suggest, thus resulting in higher plasma nitrite
concentrations. Indeed, under acidic conditions, nitrite is proto-
nated to form nitrous acid (HNO2) [5,7], and the undissociated
form of nitrous acid is found at a much higher fraction than its
dissociated form at low pH (nitrous acid pKa ¼ 3.14) [31]. There-
fore increased amounts of undissociated nitrous acid will easily
diffuse accross cell membranes and across the gastric wall into
blood circulation, where physiological pH causes the dissociated
form of nitrous acid to predominate. This important pH-
dependent partitioning of nitrous acid may result in fast increases
in plasma nitrite concentrations, as we found in the present study.
In support of this mechanism, nitrite was experimentally shown to
penetrate through biological membranes in the form of undisso-
ciated nitrous acid and accumulate in areas with high pH [31].
Other mechanisms possibly explaining how TEMPOL enhances
plasma nitrite levels may include the formation of chemical adduct
facilitating nitrite uptake, or it is possible that nitrite-derived NO
in the stomach is oxidized to nitrite by stomach oxidases asGastric
wall
blood NO2
NO2-
+
blood NO2-
EMPOL
H+
HNO2
.NO blood NO2-
blood NO2-
.NO
blood NO3-
tric nitric oxide formation and enhances the antihypertensive effects of nitrite.
J.H. Amaral et al. / Free Radical Biology and Medicine 65 (2013) 446–455454formed NO diffuses across the gastric wall into gastric vessels, thus
resulting in higher nitrite concentrations than expected. This
suggestion is based on recent studies showing that plasma
ceruplasmin [32] or lung epithelial cells [33] have NO oxidase
activity and therefore facilitate nitrite synthesis from NO. How-
ever, this possibility remains to be examined.
In parallel with the effects that we found with TEMPOL,
reducing agents such as polyphenols caused nitrite to generate
predominantly NO [14,34]. We found that treatment with TEMPOL
was associated with greater increases in plasma nitrite and lower
increases in plasma nitrate after 5 or 15 mg of sodium nitrite,
possibly as a result of a more reductive gastric environment in the
presence of TEMPOL. In fact, nitrite delivery (15 mg/kg) in the
stomach results in a plasma nitrite:nitrate ratio of 0.2:1, whereas
TEMPOL delivery with nitrite reduces the nitrate levels in plasma,
relative to nitrite alone, and increases the nitrite levels in plasma,
for a nitrite:nitrate ratio of 1.7:1. This suggests that TEMPOL
treatment increases nitrite bioavailability and reduces nitrite
oxidation to nitrate, possibly by enhanced nitrite uptake mechan-
isms. More convincingly, we showed that treatment with ome-
prazole completely blunted the effects of TEMPOL, both on plasma
nitrite concentrations and on blood pressure. These ﬁndings, both
in vitro and in vivo, consistently show that acidic conditions of the
stomach are critical for TEMPOL to enhance nitrite-derived NO
formation. As expected, the hypotensive effects of nitrite were
almost completely blunted by the NO scavenger C-PTIO, indepen-
dent of the enhancing effects of TEMPOL, and again indicate
nitrite-derived NO formation.
Our results align with previous ﬁndings showing that TEMPOL
and other nitroxides increase NO bioavailability [35], and this effect
may underlie the cardiovascular protective effects of antioxidants
and nitrate/nitrite-rich diets [36,37]. Moreover, our ﬁndings may
help to explain inconsistencies between studies showing antihy-
pertensive effects of vegetable-rich diets in patients with hyperten-
sion [38,39], whereas antioxidants apparently exert no signiﬁcant
protective effects [40,41]. It is possible that the amounts of nitrate/
nitrite may interact with antioxidants found in the diet, especially
in vegetable-rich diets and potentiate their antihypertensive effects.
Simply taking antioxidants may not be of real help, whereas
increasing nitrite/nitrate intake may result in antihypertensive
effects and lower the incidence of cardiovascular events in patients.
An important limitation of our results is that ascorbic acid is
actively secreted into the gastric juice in rats [42], and therefore
ascorbic acid may affect the ability of TEMPOL to alter NO
formation from nitrite in the stomach. Although we have not
added ascorbic acid to our in vitro experiments, this limitation is
probably not relevant to our in vivo ﬁndings, which we believe are
the most important ﬁndings in the present study.
Important implications of our ﬁndings deserve some com-
ments. TEMPOL increased NO formation from nitrite, particularly
under the acidic conditions of the stomach, and this improved the
hypotensive effects of oral nitrite. Therefore, it is possible that
TEMPOL may enhance NO formation from nitrite under other
relevant acidic conditions, for example, during tissue ischemia
[43]. While a previous study reports that reducing substances such
as thiols or ascorbate failed to increase NO formation at pH 5.5
[12], the effects of TEMPOL under such conditions are unknown
and should be tested. However, it is important to note that that co-
infusion of ascorbate with nitrite modestly potentiated the vaso-
dilatory effects of nitrite in the human forearm, possibly as a result
of ascorbate-induced decreases in redox potential [44].
If our in vitro results are conﬁrmed in vivo, it is possible that
TEMPOL facilitates NO formation from nitrite in proportion with
tissue acidosis and cellular ischemic stress [43,45,46]. However,
this suggestion requires experimental validation. If proved true, it
may have important clinical applications.In conclusion, we found that TEMPOL enhances nitrite-derived
NO formation under the acidic conditions of the stomach, and this
effect increases orally administered nitrite-induced increases in
circulating nitrite concentrations and hypotension. The effects of
TEMPOL on nitrite-mediated hypotension cannot be explained by
increased NO formation in the stomach alone, but rather appear
more directly related to increased plasma nitrite levels and
reduced nitrate levels during TEMPOL treatment. This may relate
to enhanced nitrite uptake or reduced nitrate formation from NO
or nitrite. Our ﬁndings may suggest a pharmacological approach to
maximize NO formation from nitrite under acidic conditions.Acknowledgments
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